Molecular and functional study of hematopoiesis in myeloid diseases v1

  • Research type

    Research Study

  • Full title

    Molecular and functional studies of blood and bone marrow cells from patients with myeloid disorders and from volunteers with normal blood count

  • IRAS ID

    216767

  • Contact name

    Jacqueline Boultwood

  • Contact email

    jacqueline.boultwood@ndcls.ox.ac.uk

  • Duration of Study in the UK

    9 years, 11 months, 31 days

  • Research summary

    This research project will study the genetic and cellular basis of the myelodysplastic syndromes (MDS) and of other related myeloid disorders. The MDS are a group of serious blood cancers, with patients having anaemia, frequent infection and a high risk of developing acute myeloid leukaemia (AML). MDS is as common as AML; there are few effective treatments for this disorder and the prognosis for patients with advanced disease is poor. Research is required to further our understanding of these conditions so that we can better determine how these disorders develop and progress, thereby improving diagnoses and treatment.

    Professor Boultwood’s research team at the University of Oxford is focused on an improved understanding of the cellular and genetic basis of myeloid disorders. Samples collected under an existing study (with ethical approval in place) will include blood, bone marrow, saliva, hair and nail clippings.

    The samples will be tested using a range of state-of-the-art laboratory tests, including next-generation sequencing and cell-based assays. Professor Boultwood’s research team have long established expertise in this area. These studies will allow us to gain a greater understanding of the causes of myeloid disorders and how they progress. Moreover, new therapeutic targets will be identified for these conditions, allowing for the development of new therapies.

  • REC name

    Yorkshire & The Humber - South Yorkshire Research Ethics Committee

  • REC reference

    17/YH/0322

  • Date of REC Opinion

    14 Sep 2017

  • REC opinion

    Favourable Opinion